Drug Profile
WL 8713
Alternative Names: Anticholinergic therapeutic - Actavis; WL8713Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Actavis Inc
- Developer AbbVie
- Class Skin disorder therapies
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperhidrosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 09 Sep 2016 No recent reports on development identified - Phase-II for Hyperhidrosis in USA (unspecified route)
- 01 Jun 2014 Watson Pharmaceuticals completes a phase II trial in Hyperhidrosis in USA (NCT02193139)